[go: up one dir, main page]

MXPA01011344A - The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders. - Google Patents

The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders.

Info

Publication number
MXPA01011344A
MXPA01011344A MXPA01011344A MXPA01011344A MXPA01011344A MX PA01011344 A MXPA01011344 A MX PA01011344A MX PA01011344 A MXPA01011344 A MX PA01011344A MX PA01011344 A MXPA01011344 A MX PA01011344A MX PA01011344 A MXPA01011344 A MX PA01011344A
Authority
MX
Mexico
Prior art keywords
prophylactic
tyrosine kinase
protein tyrosine
kinase pathway
therapeutic treatment
Prior art date
Application number
MXPA01011344A
Other languages
Spanish (es)
Inventor
Juan Eugene De Jr
Original Assignee
Univ Johns Hopkins Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins Med filed Critical Univ Johns Hopkins Med
Publication of MXPA01011344A publication Critical patent/MXPA01011344A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)

Abstract

La presente invencion esta dirigida a un metodo para el tratamiento profilactico y terapeutico de la degeneracion macular relacionada con la edad asi como a metodos para el tratamiento profilactico y terapeutico de las complicaciones exudativas y atroficas de la degeneracion macular relacionada con la edad. Los metodos implican la administracion de un inhibidor de la ruta de la proteina tirosina quinasa a un animal, tal como un mamifero, en particular un humano, en una cantidad suficiente para tratar al animal respecto a la degeneracion macular relacionada con la edad o a una complicacion exudativa o atrofica de la misma, respectivamente, en forma profilactica o terapeutica. La presente invencion provee tambien un metodo para el tratamiento profilactico y terapeutico de la degeneracion de la retina, un metodo para el tratamiento profilactico y terapeutico de la degeneracion de la coroide y un metodo para el tratamiento profilactico y terapeutico del engrosamiento de la membrana de Bruch. Estos metodos implican la administracion de un inhibidor de la ruta de la proteina tirosina quinasa a un animal, tal como un mamifero, en particular un humano, en una cantidad suficiente par tratar la macula, retina, coroide o membrana de Bruch, respectivamente, en forma profilactica o terapeutica. De preferencia el inhibidor de la ruta de la proteina tirosina quinasa es genisteina o un analogo o profarmaco de la misma o una sal farmaceuticamente aceptable de cualquiera de los anteriores.The present invention is directed to a method for the prophylactic and therapeutic treatment of age-related macular degeneration as well as to methods for the prophylactic and therapeutic treatment of exudative and atrophic complications of age-related macular degeneration. The methods involve the administration of an inhibitor of the protein tyrosine kinase pathway to an animal, such as a mammal, in particular a human, in an amount sufficient to treat the animal with respect to age-related macular degeneration or a complication. exudative or atrophic thereof, respectively, prophylactically or therapeutically. The present invention also provides a method for the prophylactic and therapeutic treatment of retinal degeneration, a method for the prophylactic and therapeutic treatment of choroidal degeneration and a method for the prophylactic and therapeutic treatment of Bruch's membrane thickening. . These methods involve the administration of an inhibitor of the protein tyrosine kinase pathway to an animal, such as a mammal, in particular a human, in an amount sufficient to treat Bruch's macula, retina, choroid or membrane, respectively, in prophylactic or therapeutic form. Preferably, the protein tyrosine kinase pathway inhibitor is genistein or an analogous or prodrug thereof or a pharmaceutically acceptable salt of any of the foregoing.

MXPA01011344A 1999-05-07 2000-05-05 The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders. MXPA01011344A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13311299P 1999-05-07 1999-05-07
US35044099A 1999-07-09 1999-07-09
PCT/US2000/012339 WO2000067738A2 (en) 1999-05-07 2000-05-05 The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders

Publications (1)

Publication Number Publication Date
MXPA01011344A true MXPA01011344A (en) 2004-06-03

Family

ID=26831056

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01011344A MXPA01011344A (en) 1999-05-07 2000-05-05 The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders.

Country Status (6)

Country Link
EP (1) EP1178791A2 (en)
JP (1) JP4920134B2 (en)
AU (1) AU774495B2 (en)
CA (1) CA2373178C (en)
MX (1) MXPA01011344A (en)
WO (1) WO2000067738A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2826276A1 (en) * 2001-06-20 2002-12-27 Raouf Rekik Ophthalmological medicament for correcting vision and abrogating the need for glasses, contains an angiotension conversion enzyme inhibitor
US7771742B2 (en) * 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
TW200640443A (en) * 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
US20070149593A1 (en) * 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US10010447B2 (en) 2013-12-18 2018-07-03 Novartis Ag Systems and methods for subretinal delivery of therapeutic agents
US12035973B2 (en) 2018-01-25 2024-07-16 Osaka University Method for detecting stressed state and stress detection apparatus
CN114931574A (en) * 2022-06-14 2022-08-23 深圳爱尔眼科医院 Iron death inhibitor and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09316000A (en) * 1996-05-31 1997-12-09 Toagosei Co Ltd Vaccine for suppressing arterialization
DK1920773T3 (en) * 1996-11-05 2011-03-28 Childrens Medical Center Thalidomide and dexamethasone for the treatment of tumors
AU6553998A (en) * 1997-03-14 1998-09-29 Regents Of The University Of California, The Methods for inhibiting bacterial cytotoxicity
EP1017682A4 (en) * 1997-09-26 2000-11-08 Merck & Co Inc NEW ANGIOGENESIS INHIBITORS
DE69936381T2 (en) * 1998-03-13 2007-10-31 The Johns Hopkins University School Of Medicine USE OF A PROTEIN KINASE HEMMER LIKE. GENISTE IN THE TREATMENT OF DIABETIC RETINOPATHY

Also Published As

Publication number Publication date
CA2373178C (en) 2013-07-02
EP1178791A2 (en) 2002-02-13
CA2373178A1 (en) 2000-11-16
WO2000067738A2 (en) 2000-11-16
JP4920134B2 (en) 2012-04-18
AU4988400A (en) 2000-11-21
JP2002544159A (en) 2002-12-24
WO2000067738A3 (en) 2001-08-23
AU774495B2 (en) 2004-07-01

Similar Documents

Publication Publication Date Title
CA2321560A1 (en) The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation
MX2010003774A (en) Aqueous ophthalmic formulations.
TW200833341A (en) 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions
CO2022000659A2 (en) Imidazo[1,2-a]pyridinyl derivatives and their use in the treatment of diseases
TW200633709A (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions
CA2502437A1 (en) Method and composition containing latanoprost for treating ocular hypertension and glaucoma
BR0312232A (en) Caspase inhibitors and their uses
ES2159209T3 (en) USE OF ACID 11- (3-DIMETHYLAMOPROPILIDEN) -6,11-DIHIDRODIBENZ (B, E) OXEPIN-2-ACETIC AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF NON-ALBUM ADMINISTRATION OF OCULAR NEOVASCULARIZATION.
CA2582316A1 (en) Use of inhibitors of jun n-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
MXPA01011344A (en) The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders.
CA2314571A1 (en) Methods and compositions for treating diseases and conditions of the eye
WO2006039252A3 (en) Compositions and methods for treating ophthalmic diseases
CL2020001426A1 (en) Topical ophthalmic composition comprising dobesilic acid to treat diseases of the posterior segment of the eye.
EP1037622A4 (en) Taurine derivatives usable in the treatment of ophthalmic disorders
MXPA03001160A (en) Method of treating neurodegenerative disorders of the retina and optic nerve head.
WO2005102303A3 (en) Antiprostaglandins for the treatment of ocular pathologies
CY1108572T1 (en) MEDICINES FOR DISEASES OF AMONG AND HUMAN EXTRACTS CONTAINING STEEROID AS AN ACTIVE INGREDIENT
IT1276462B1 (en) ACID AROMATIC DIAMIDES WITH ANTIGASTRINIC ACTIVITY, PROCEDURE FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL USE
ATE325618T1 (en) USE OF NERVE GROWTH FACTOR IN THE PRODUCTION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DISEASES OF THE INNER EYE TISSUES
BR0114339A (en) Pharmaceutically acceptable compositions containing epinastine and pseudoephedrine
BRPI0411427A (en) Nonsteroidal Anti-Inflammatory Agents Formulations for the Treatment of Pathological Eye Angiogenesis
PT1259229E (en) UTILIZATION OF BENZOTIENO- [2,3-D] -PYRIMIDINES WITH AN INHIBITOR ACTION OF PDE V IN THE TREATMENT OF ERECTILE DISFUNCTION
ES2289134T3 (en) USE OF NON-FEMINIZING STROGENS AS PROTECTIVE AGENTS OF RETINA FOR THE TREATMENT OF GLAUCOMA.
ROBERTSON GAS BACILLUS INFECTION—A REPORT OF SIX CASES
Weissman Risk of corneal infection and extended wear of contact lenses

Legal Events

Date Code Title Description
FG Grant or registration